

**TABLE 2. THERAPEUTICS AT BASELINE IN RELATION TO CARDIOMYOPATHY SUBTYPES**

	HCM (N=1739)	DCM (N=1260)	RCM (N=66)	ARVC (N=143)	P-value
<b>Procedures prior to enrollment :</b>					
Cardioverter defibrillator implanted, n(%)	346/1739 (19.9%)	399/1260 (31.7%)	6/66 (9.1%)	81/143 (56.6%)	<0.001
Reason for cardioverter defibrillator, n(%)					
Primary prophylaxis	297/346 (85.8%)	331/399 (83.0%)	3/6 (50.0%)	46/81 (56.8%)	<0.001 †
Secondary prophylaxis	49/346 (14.2%)	68/399 (17.0%)	3/6 (50.0%)	35/81 (43.2%)	
Pacemaker implanted, n(%)	135/1723 (7.8%)	177/1240 (14.3%)	8/65 (12.3%)	4/141 (2.8%)	<0.001
Septal myectomy, n(%)	85/1739 (4.9%)	-	-	-	
Alcohol septal ablation, n(%)	70/1739 (4.0%)	-	-	-	
Cardiac ablation*, n(%)	62/1739 (3.6%)	44/1260 (3.5%)	2/66 (3.0%)	16/143 (11.2%)	<0.001
<b>Medications :</b>					
Beta-blockers, n(%)	1294/1739 (74.4%)	1130/1260 (89.7%)	42/66 (63.6%)	119/143 (83.2%)	<0.001
Diuretics, oral, n(%)	491/1563 (31.4%)	895/1247 (71.8%)	53/62 (85.5%)	24/131 (18.3%)	<0.001
ACE-inhibitors, n(%)	342/1739 (19.7%)	917/1260 (72.8%)	15/66 (22.7%)	33/143 (23.1%)	<0.001
Angiotensin II receptorblockers, n(%)	265/1739 (15.2%)	210/1260 (16.7%)	7/66 (10.6%)	11/143 (7.7%)	0.026
Mineralocorticoid receptor antagonists, n(%)	233/1739 (13.4%)	795/1260 (63.1%)	30/66 (45.5%)	17/143 (11.9%)	<0.001
Antiplatelets, n(%)	420/1739 (24.2%)	299/1260 (23.7%)	15/66 (22.7%)	26/143 (18.2%)	0.451
Oral anticoagulants, n(%)	424/1561 (27.2%)	443/1246 (35.6%)	36/62 (58.1%)	19/131 (14.5%)	<0.001
Vit K antagonists	296/1561 (19.0%)	345/1246 (27.7%)	24/62 (38.7%)	15/131 (11.5%)	
All other (rivaroxaban, apixaban, dabigatran, other)	128/1561 (8.2%)	98/1246 (7.9%)	12/62 (19.4%)	4/131 (3.1%)	<0.001
Anti-arrhythmic drugs, n(%)	264/1739 (15.2%)	361/1260(28.7%)	12/66 (18.2%)	34/143 (23.8%)	<0.001

HCM=Hypertrophic Cardiomyopathy

DCM=Dilated Cardiomyopathy

RCM=Restrictive Cardiomyopathy

ARVC=Arrhythmogenic right ventricular Cardiomyopathy

\*whatever reason (atrial or ventricular arrhythmia)

† : Fisher exact test